Jon Kaufman, PhD
Chief Executive Officer
Dr. Kaufman co-founded Lipella and has served as CEO since the company’s 2005 inception. In his career, he helped co-found Knopp Biosciences, which signed a deal with Biogen Idec for $345M (2010), and served as CFO of Semprus Biosciences, which sold to Teleflex for $80M (2012).

Dr. Kaufman has been Lipella’s principal investigator for federal grant programs to fund its pre-clinical and clinical programs. He also manages operations, as well as relationships with existing investors and corporate partners.

Dr. Kaufman earned his PhD in Biophysics from the University of Pennsylvania School of Medicine and his MBA in Finance from the Wharton School.
Michael Chancellor, MD
As an internationally recognized expert in the treatment of urinary bladder dysfunction, Dr. Michael Chancellor is a key opinion leader in the field. He has conducted over 75 clinical trials and has consulted with numerous biotech companies developing urology products. His client list includes Pfizer, Merck, J&J, Lilly, AstraZeneca, Allergan, Astellas, P&G, and Indevus. He has extensive experience in clinical trial design and FDA communications.

In 2005, Dr. Chancellor co-founded Lipella and has served as the company's CMO since then. In 2008, he joined Lipella full-time, while maintaining a part-time academic appointment at the William Beaumont Medical Center.

A board-certified urologist, Dr. Chancellor earned his MD from the University of Michigan.
Tom Petzinger, Jr
Tom Petzinger is founder, Chairman, President and CEO of LaunchCyte LLC, a development company that creates, seeds, and harvests life sciences innovations from leading research universities across the U.S. Currently, LaunchCyte has six life sciences portfolio companies, with a combined value of approximately $150 million. In addition to leading LaunchCyte, Tom is Executive Vice President, Business Development & Public Affairs for Knopp Neurosciences.

Prior to founding LaunchCyte, Tom spent 22 years at The Wall Street Journal, where he served as Washington economics editor, deputy Washington bureau chief, millennium editor, and weekly columnist. Tom received his B.S. in Journalism from Northwestern University, where he was a Richter International Scholar.
David Battleman, MD
Prior to establishing his own consulting firm, TrueNorth Lifesciences, Dr. David Battleman served as a senior principal in the Pricing and Market Access (P&MA) practice within IMS Health, a global Fortune 500 company providing lifescience data and consulting services to the pharmaceutical industry. Prior to joining IMS, Dr. Battleman served as senior director / executive director for Pfizer Pharmaceuticals where he was responsible for developing value-based product strategy and communications across Pfizer's cardiovascular portfolio, ranging from early-stage to marketed products.

And within academia, Dr. Battleman was an assistant professor of public health and medicine at Cornell University's Weill Cornell Medical College. There, Dr. Battleman's research focused primarily on the areas of quality measurement and value assessment in healthcare and he has published both original research and expert reviews in these areas. Dr. Battleman holds an M.D. from Weill Cornell Medical College, an M.B.A. from the University of Pennsylvania's Wharton School, and an M.Sc. in epidemiology from the Harvard School of Public Health. He is also a board-certified internist.
David Lucchino
David L. Lucchino co-founded and served as Chief Executive Officer and President of Semprus BioSciences, a spin out from the lab of Robert S. Langer at MIT, until its acquisition by Teleflex Medical, Inc. (NYSE: TFX) for $80 million, where he subsequently served as Vice President of Sustainª Technology. Prior to co-founding Sustainª Technology (formerly Semprus Biosciences), David was a senior executive at Polaris Venture Partners, a $3B venture capital fund based in Boston. He is a Trustee of Mt. Auburn Hospital, a Harvard Medical School facility, a member of the board of directors for the Advanced Medical Technology Association (AdvaMed) in Washington and the Massachusetts Biotechnology Council (Mass BIO), a not-for-profit organization that supports Massachusetts biotechnology industry. David earned an M.B.A. from MIT's Sloan School of Management as an Alfred P. Sloan Fellow, an M.S. from Syracuse University and a B.A. from Denison University.